NCT06388772View on ClinicalTrials.gov

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

July 22, 2022

Study Completion Date

January 6, 2023

Conditions
Acute Ischemic Stroke
Interventions
DRUG

QHRD106 Injection

250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1

DRUG

placebo

placebo

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

Sponsors
All Listed Sponsors
lead

Changzhou Qianhong Bio-pharma Co., Ltd.

INDUSTRY

NCT06388772 - Study to Assess PK, Safety and Tolerability Early in Healthy Subjects | Biotech Hunter | Biotech Hunter